Please ensure Javascript is enabled for purposes of website accessibility

Illumina and Roche Combine For Genomics Oncology Deal

By Eric Volkman - Jan 14, 2020 at 3:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The two companies aim to make significant advances in cancer research and make genomics accessible to more patients.

Top DNA sequencing company Illumina (ILMN 0.08%) has signed a pact with global pharmaceutical giant Roche (RHHBY 0.93%) in the field of oncology, the Illumina's CEO Francis deSouza announced.

On Monday, deSouza shared the news at the high-profile annual J.P. Morgan Healthcare Conference that his company and Roche signed a 15-year non-exclusive collaboration deal centered around next-generation sequencing (NGS) diagnostics in the field of oncology.

3 strands of DNA.

Image source: Getty Images

The mechanics of the deal are that Roche will hold rights to "develop and distribute in-vitro diagnostic (IVD) tests on Illumina's NextSeq 550Dx System, as well as on its future portfolio of diagnostic (Dx) sequencing systems, including the forthcoming NovaSeqDx," according to a subsequent Illumina press release.

For its part, "Roche will in turn collaborate with Illumina to complement Illumina's comprehensive pan-cancer assay, TruSight Oncology 500 (TSO 500), with new companion diagnostic (CDx) claims."

Under the terms of their arrangement, Roche will have the right to develop, produce and sell IVD testing products to be used on the NextSeq 550Dx. The two companies will additionally collaborate to develop tests and CDx claims for oncology treatments on that system.

Neither Illumina nor Roche provided the financial terms of their new collaboration. The two also did not provide estimates as to how it would impact their respective businesses. They did tout the synergistic benefits of the tie-up. In its own press release, Roche said the deal "leverage[s] our combined expertise in clinical oncology and next-generation sequencing."

Despite the promising news, neither healthcare stock is seeing a bounce. Illumina's stock is down slightly in late afternoon trading. Roche's stock remains flat. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Roche Holding AG Stock Quote
Roche Holding AG
$40.12 (0.93%) $0.37
Illumina, Inc. Stock Quote
Illumina, Inc.
$233.74 (0.08%) $0.18

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.